Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of 177Lu-PentixaTher radioligand therapy in relapsed/refractory CXCR4-positive acute leukemia
2022-501019-15-00Phase 2Authorised
- Sponsor
- CHU de Nantes
- Start
- Mar 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of pentixather in Acute Leukaemia, sponsored by CHU de Nantes. Planned start Mar 2024; status: authorised.
02
Drugs
pentixather
03
Conditions
Acute Leukaemia
Beyond the preview
Go deeper on 2022-501019-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501019-15-00.